By: Kerri Fitzgerald
Ongoing results from the DREAMM-8 trial reinforced the clinically meaningful progression-free survival (PFS) benefit of belantamab mafodotin, pomalidomide, and dexamethasone (BPd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed or refractory multiple myeloma (MM).
The study was presented by Meletios Dimopoulos, MD, of the National and Kapodistrian University of Athens, as part of the SOHO 2025 Annual Meeting.
Patients (n=302) were randomized 1:1 to received BPd (B, 2.5 mg/kg intravenously in cycle 1 then 1.9 mg/kg in cycle 2 and beyond; P, 4 mg; d, 40 mg) (n=155) or PVd (P, 4 mg; V, 1.3 mg/m2 subcutaneously; d, 20 mg) (n=147) until disease progression, unacceptable toxicity, or death.
After a median follow-up of 28.01 months, 35% (n=55) of patients in the BPd arm and 14% (n=20) in the PVd arm were still receiving treatment. The PFS benefit was maintained and favored BPd: median PFS was 32.6 months with BPd and 12.5 months with PVd (hazard ratio [HR], 0.49; 95% CI, 0.35-0.68). The 18-month PFS rates were 63% and 41%, respectively.
The benefit of BPd was observed across subgroups, including in patients with:
- High-risk cytogenetics (HR, 0.55)
- Lenalidomide-refractory disease (HR,0.43)
- Anti-CD38-refractory disease (HR, 0.64)
- One prior line of therapy (HR, 0.47)
- Two or more prior lines of therapy (HR, 0.51).
Safety outcomes “were consistent with those from the primary analysis,” according to the authors.
“These data further support BPd as a potential standard-of-care option in patients with [relapsed or refractory] MM,” the researchers noted.
The study was funded by GSK.
Reference
Dimopoulos M, Beksac M, Pour L, et al. Updated results from the phase 3 DREAMM-8 study of belantamab mafodotin (belamaf) plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma. Abstract #MM-1045. Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 3-6, 2025; Houston, Texas.
Visit the SOHO 2025 meeting news page for more coverage from the meeting.
